Glenmede Trust’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-5,534
| Closed | -$92K | – | 2508 |
|
|
2018
Q1 | $92K | Hold |
5,534
| – | – | ﹤0.01% | 1424 |
|
|
2017
Q4 | $92K | Buy |
5,534
+5,338
| +2,723% | +$97.8K | ﹤0.01% | 1424 |
|
|
2017
Q3 | $3K | Hold |
196
| – | – | ﹤0.01% | 2531 |
|
|
2017
Q2 | $2K | Hold |
196
| – | – | ﹤0.01% | 2542 |
|
|
2017
Q1 | $2K | Buy |
196
+157
| +403% | +$1.9K | ﹤0.01% | 2542 |
|
|
2016
Q4 | $0 | Hold |
39
| – | – | ﹤0.01% | 2712 |
|
|
2016
Q3 | $0 | Hold |
39
| – | – | ﹤0.01% | 2741 |
|
|
2016
Q2 | $0 | Sell |
39
-343
| -90% | -$11.2K | ﹤0.01% | 2808 |
|
|
2016
Q1 | $11K | Buy |
382
+95
| +33% | +$3.34K | ﹤0.01% | 2026 |
|
|
2015
Q4 | $11K | Hold |
287
| – | – | ﹤0.01% | 2051 |
|
|
2015
Q3 | $9K | Sell |
287
-4,314
| -94% | -$194K | ﹤0.01% | 2152 |
|
|
2015
Q2 | $210K | Buy |
4,601
+148
| +3% | +$7.03K | ﹤0.01% | 1202 |
|
|
2015
Q1 | $208K | Buy |
+4,453
| New | +$177K | ﹤0.01% | 1235 |
|
|
2014
Q3 | – | Sell |
-6,304
| Closed | -$189K | – | 2541 |
|
|
2014
Q2 | $189K | Hold |
6,304
| – | – | ﹤0.01% | 1191 |
|
|
2014
Q1 | $166K | Sell |
6,304
-13,375
| -68% | -$334K | ﹤0.01% | 1238 |
|
|
2013
Q4 | $494K | Hold |
19,679
| – | – | 0.01% | 865 |
|
|
2013
Q3 | $402K | Hold |
19,679
| – | – | ﹤0.01% | 886 |
|
|
2013
Q2 | $392K | Buy |
+19,679
| New | +$349K | ﹤0.01% | 840 |
|
Glenmede Trust's IPXL Position: Q2 2018 in Review
Glenmede Trust sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 5,534 shares — an estimated $92K sold.
Glenmede Trust first reported a position in IPXL in Q2 2013 and held it in 18 quarters. The position peaked at $494K in Q4 2013. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Glenmede Trust reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Glenmede Trust sold 5,534 Impax Laboratories, Inc. shares in Q2 2018, an estimated $92K.
- Glenmede Trust first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 18 quarters.
- Glenmede Trust's Impax Laboratories, Inc. position peaked at $494K in Q4 2013.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Glenmede Trust's 13F filing for Q2 2018, filed 15 Aug 2018.